Vitiligo treatment aims to arrest active skin depigmentation and stimulate residual pigment-producing cells, known as melanocytes, to re-establish normal skin color. The treatment falls primarily under the medical category of clinical dermatology. Therapeutic mechanisms focus on suppressing local immune-mediated tissue injury, facilitating melanocyte stem cell migration from hair follicles, and grafting healthy pigment cells into stable, unresponsive skin lesions.

Vitiligo management protocol varies by clinical subtype. For topical therapy, precise application of corticosteroids or Janus kinase (JAK) inhibitors is performed twice daily on depigmented lesions. Phototherapy involves scheduled exposure to 311–312 nm Narrowband UVB radiation inside a specialized light chamber, starting at minimal erythema doses and titrated incrementally. Surgical protocols involve harvesting donor skin from an pigmented area (e.g., thigh), extracting cellular suspensions or epidermal sheets via enzymatic digestion or suction blistering, dermabrasion of the recipient target site, and securing the graft with biological dressings.

Evidence-based clinical benefits of vitiligo treatment include: halting active spreading of white patches (disease stabilization), restoration of natural skin pigmentation (repigmentation), reduction of epidermal inflammatory cytokines, protection of structural skin integrity against actinic damage in depigmented zones, and improved quality-of-life scores measured by standardized dermatological scales.

Recovery timelines vary significantly by treatment modality. Topical medical therapies show initial perifollicular repigmentation within 8 to 12 weeks. Phototherapy typically requires 6 to 12 months of consistent sessions for maximum efficacy. Surgical interventions, such as tissue or cellular grafting, require strict immobility for 7 to 14 days post-procedure, with full pigment spreading and color matching maturing over 6 to 12 months.

Vitiligo treatment addresses non-segmental vitiligo (generalized, acrofacial, mucosal, and universal patterns), segmental vitiligo, focal vitiligo, and post-inflammatory hypopigmentation. It targets active progressive depigmentation, localized chalk-white macules, and hair whitening (known as poliosis) associated with follicular melanocyte depletion.

Pre-treatment evaluation includes assessment of vitiligo disease activity, Wood's lamp mapping, baseline laboratory screening (thyroid function tests, antinuclear antibodies), phototype determination, and evaluation for Koebner phenomenon (isomorphic response to trauma). Patients undergoing phototherapy must stop photosensitizing medications. Surgical candidates must show disease stability for a minimum of 6 to 12 months.

Common side effects include localized skin redness (erythema), mild itching, dry skin, and superficial skin thinning (atrophy) from prolonged topical steroid use. Phototherapy carries risks of mild sunburn-like erythema and hyperpigmentation of surrounding normal skin. Surgical risks include graft failure, hyperpigmentation, cobblestoning texture, infection, and secondary scarring.

Clinical Patient Journey

The patient journey begins with a clinical evaluation, including wood's lamp examination and assessment of disease activity (active vs. stable vitiligo). The initial treatment phase typically involves topical immunomodulators or systemic corticosteroids for rapid stabilization. If lesions are widespread, patients undergo a multi-month course of narrowband ultraviolet B phototherapy 2 to 3 times weekly. Patients with recalcitrant, long-standing stable lesions may be evaluated for surgical cell transplantation. Long-term follow-up involves periodic clinical scoring, maintenance topicals, and strict photo-protection.